Pleural empyema medical therapy: Difference between revisions
No edit summary |
|||
Line 83: | Line 83: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[Cefotaxime]] 100 mg/kg IV q8h''''' <br>OR<br>'''''[[Ceftriaxone]] 100 mg/kg IV q24h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[Cefotaxime]] 100 mg/kg IV q8h''''' <br>OR<br>'''''[[Ceftriaxone]] 100 mg/kg IV q24h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ''''''If MSSA''''' <br>▸''''' [[Vancomycin]] 40 mg/kg/day IV in 3-4 divided doses'''''<br>'''''With or Without'''''<br> ''''''[[Cefotaxime]] 100 mg/kg IV q8h''''' <br>OR<br>'''''[[Ceftriaxone]] 100 mg/kg IV q24h'''''<br>'''''If H.Influenzae suspected''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ''''''If MSSA''''' <br>▸''''' [[Vancomycin]] 40 mg/kg/day IV in 3-4 divided doses'''''<br>'''''With or Without'''''<br>▸ ''''''[[Cefotaxime]] 100 mg/kg IV q8h''''' <br>OR<br>▸'''''[[Ceftriaxone]] 100 mg/kg IV q24h'''''<br>'''''If H.Influenzae suspected''''' | ||
|} | |} | ||
|} | |} | ||
Line 100: | Line 100: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | For Staph. aureus | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | For Staph. aureus | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''MSSA''''' <br>''''' [[Nafcillin]]2 gm IV q4h''''' <br>OR<br>''''' [[Oxacillin]] 2 gm IV q4h ''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''MSSA''''' <br>''''' [[Nafcillin]]2 gm IV q4h''''' <br>OR<br>▸''''' [[Oxacillin]] 2 gm IV q4h ''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''MRSA''''' <br>'''''[[Vancomycin]] 10-15 mg/kg IV q8-12h''''' <br>OR<br>''''' [[Linezolid]] 600 mg IV q12h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''MRSA''''' <br>'''''[[Vancomycin]] 10-15 mg/kg IV q8-12h''''' <br>OR<br>▸''''' [[Linezolid]] 600 mg IV q12h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | For H. influenzae | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | For H. influenzae | ||
Line 114: | Line 114: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center| PLUS | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center| PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''''[[Ceftriaxone]] 2 gm IV q24h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[Ceftriaxone]] 2 gm IV q24h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimens''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimens''''' | ||
Line 128: | Line 128: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''''Chronic''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''''Chronic''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[Cefoxitin]] 2 gm IV q6-8h''''' <br>OR<br> '''''[[Imipenem]] 0.5 gm IV q6h'''''<br>OR<br> '''''[[Piperacillin Tazobactam]] 3.375 gm IV q6h (or 4-hour infusion of 3.375 gm q8h)'''''<br>OR<br>'''''[[Ampicillin Sulbactam]] 3 gm IV q6h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[Cefoxitin]] 2 gm IV q6-8h''''' <br>OR<br>▸ '''''[[Imipenem]] 0.5 gm IV q6h'''''<br>OR<br>▸ '''''[[Piperacillin Tazobactam]] 3.375 gm IV q6h (or 4-hour infusion of 3.375 gm q8h)'''''<br>OR<br>▸'''''[[Ampicillin Sulbactam]] 3 gm IV q6h''''' | ||
|} | |} | ||
|} | |} |
Revision as of 03:04, 3 February 2014
Pleural empyema Microchapters |
Diagnosis |
Treatment |
Case Studies |
Pleural empyema medical therapy On the Web |
American Roentgen Ray Society Images of Pleural empyema medical therapy |
Risk calculators and risk factors for Pleural empyema medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Medical Therapy
Definitive treatment for empyema entails drainage of the infected pleural fluid. A chest tube may be inserted, often using ultrasound guidance. Intravenous antibiotics are given. If this is insufficient, surgical debridement of the pleural space may be required.
Antibiotic Therapy
Following are the guidelines to treat Pleural empyema .[1][2]
▸ Click on the following categories to expand treatment regimens.
Pleural Empyema ▸ Neonates ▸ Infants/Children ▸ Adult |
|
|
|
Surgical management
- Antibiotic treatment should be continued for atleast 4 to 6 weeks. Sometimes it may be needed for a longer time. A CT and chest tube output should be used to confirm a complete fluid drainage with no residual locules present.
- Other modes of draining pleural fluid are tube thoracostomy, video-assisted thoracoscopic surgery (VATS), open decortication, and open thoracostomy.
Tube thoracostomy
- Least invasive
- Preferred for unilocuated effusions and free-flowing fluid.
- For solitary lesions a CT scan or ultrasound is used to guide the tube.
- For lesions more than one multiple small catheters are used to drain.
- When draining empyema fluid, thoracostomy tubes are typically placed using either an ultrasound or CT-guided approach. When multiple loculations are present, we typically place small-bore catheters, as multiple tubes may be needed to drain the multiloculated pleural space.
- A trial showed no difference between different sizes of thoracostomy tube. Smaller tubes were preferred due to decreased pain.[3][4]
- British thoracic society recommends flushing the tube every 6 hrs to remain patent.[5]. Smaller tubes are more prone to failure due to blockage.[6]. Chest tubes are placed atleast till the cavity closes or drainage falls below 50 ml/day.
- Confirm correct placement of the tube using CT scans and checking drainage .
References
- ↑ Bradley, JS.; Byington, CL.; Shah, SS.; Alverson, B.; Carter, ER.; Harrison, C.; Kaplan, SL.; Mace, SE.; McCracken, GH. (2011). "The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America". Clin Infect Dis. 53 (7): e25–76. doi:10.1093/cid/cir531. PMID 21880587. Unknown parameter
|month=
ignored (help) - ↑ Rahman, NM.; Maskell, NA.; West, A.; Teoh, R.; Arnold, A.; Mackinlay, C.; Peckham, D.; Davies, CW.; Ali, N. (2011). "Intrapleural use of tissue plasminogen activator and DNase in pleural infection". N Engl J Med. 365 (6): 518–26. doi:10.1056/NEJMoa1012740. PMID 21830966. Unknown parameter
|month=
ignored (help) - ↑ Maskell, NA.; Davies, CW.; Nunn, AJ.; Hedley, EL.; Gleeson, FV.; Miller, R.; Gabe, R.; Rees, GL.; Peto, TE. (2005). "U.K. Controlled trial of intrapleural streptokinase for pleural infection". N Engl J Med. 352 (9): 865–74. doi:10.1056/NEJMoa042473. PMID 15745977. Unknown parameter
|month=
ignored (help) - ↑ Rahman, NM.; Maskell, NA.; Davies, CW.; Hedley, EL.; Nunn, AJ.; Gleeson, FV.; Davies, RJ. (2010). "The relationship between chest tube size and clinical outcome in pleural infection". Chest. 137 (3): 536–43. doi:10.1378/chest.09-1044. PMID 19820073. Unknown parameter
|month=
ignored (help) - ↑ Davies, CW.; Gleeson, FV.; Davies, RJ. (2003). "BTS guidelines for the management of pleural infection". Thorax. 58 Suppl 2: ii18–28. PMID 12728147. Unknown parameter
|month=
ignored (help) - ↑ Horsley, A.; Jones, L.; White, J.; Henry, M. (2006). "Efficacy and complications of small-bore, wire-guided chest drains". Chest. 130 (6): 1857–63. doi:10.1378/chest.130.6.1857. PMID 17167009. Unknown parameter
|month=
ignored (help)